Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ immunology
Child
Democratic Republic of the Congo
Disease Outbreaks
/ prevention & control
Ebola Vaccines
/ immunology
Ebolavirus
/ immunology
Female
Glycoproteins
/ immunology
Hemorrhagic Fever, Ebola
/ immunology
Humans
Immunogenicity, Vaccine
/ immunology
Male
Middle Aged
Seroepidemiologic Studies
Vaccination
/ methods
Viral Envelope Proteins
/ immunology
Young Adult
Democratic Republic of the Congo
Ebola vaccine
Ebola virus disease
immunogenicity
rVSVΔG-ZEBOV-GP
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
08 02 2022
08 02 2022
Historique:
accepted:
17
12
2021
entrez:
3
2
2022
pubmed:
4
2
2022
medline:
25
2
2022
Statut:
ppublish
Résumé
Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examines the antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among EVD-exposed and potentially exposed populations in the DRC. We conducted a longitudinal cohort study of 608 rVSVΔG-ZEBOV-GP-vaccinated individuals during an EVD outbreak in North Kivu Province, DRC. Participants provided questionnaires and blood samples at three study visits (day 0, visit 1; day 21, visit 2; and month 6, visit 3). Anti-GP immunoglobulin G (IgG) antibody titers were measured in serum by the Filovirus Animal Nonclinical Group anti-Ebola virus GP IgG enzyme-linked immunosorbent assay. Antibody response was defined as an antibody titer that had increased fourfold from visit 1 to visit 2 and was above four times the lower limit of quantification at visit 2; antibody persistence was defined as a similar increase from visit 1 to visit 3. We then examined demographics for associations with follow-up antibody titers using generalized linear mixed models. A majority of the sample, 87.2%, had an antibody response at visit 2, and 95.6% demonstrated antibody persistence at visit 3. Being female and of young age was predictive of a higher antibody titer postvaccination. Antibody response and persistence after Ebola vaccination was robust in this cohort, confirming findings from outside of the DRC.
Identifiants
pubmed: 35110410
pii: 2118895119
doi: 10.1073/pnas.2118895119
pmc: PMC8833182
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Ebola Vaccines
0
Glycoproteins
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : K23 AI146268
Pays : United States
Organisme : NIAID NIH HHS
ID : L30 AI126521
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM130900
Pays : United States
Informations de copyright
Copyright © 2022 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Vaccine. 2019 Nov 15;37(48):7190-7200
pubmed: 28890191
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Lancet Infect Dis. 2018 Jul;18(7):738-748
pubmed: 29627147
Expert Rev Vaccines. 2008 May;7(4):467-79
pubmed: 18444893
J Infect Dis. 2019 Jan 29;219(4):517-525
pubmed: 30239838
Sci Data. 2017 Jan 31;4:160133
pubmed: 28140390
Vaccine. 2009 May 26;27(25-26):3319-23
pubmed: 19200827
J Law Biosci. 2020 Jan 16;7(1):lsz019
pubmed: 34221434
N Engl J Med. 2017 Jan 26;376(4):330-341
pubmed: 25830322
Future Microbiol. 2020 Jan;15:85-106
pubmed: 32030996
J Glob Health. 2019 Dec;9(2):020311
pubmed: 31656600
PLoS One. 2019 Apr 18;14(4):e0215457
pubmed: 30998735
Aging Cell. 2015 Jun;14(3):309-21
pubmed: 25720438
Lancet. 2019 Nov 23;394(10212):1893
pubmed: 31777382
Physiology (Bethesda). 2015 Nov;30(6):408-16
pubmed: 26525340
Trials. 2021 Sep 1;22(1):583
pubmed: 34470655
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
BMC Infect Dis. 2016 Jun 10;16:263
pubmed: 27286990
Immun Ageing. 2019 Sep 13;16:25
pubmed: 31528180
Chest. 2020 Jan;157(1):42-46
pubmed: 31518557
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15
pubmed: 25573105
J Infect Dis. 2018 Jan 30;217(4):529-537
pubmed: 29329455
J Infect Dis. 2019 Apr 19;219(10):1634-1641
pubmed: 30561672
MMWR Morb Mortal Wkly Rep. 2020 Jan 10;69(1):10-13
pubmed: 31917781
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
Annu Rev Cell Dev Biol. 2017 Oct 6;33:577-599
pubmed: 28992436
N Engl J Med. 2021 Apr 1;384(13):1240-1247
pubmed: 33789012
Immunol Lett. 1998 Nov;64(1):9-15
pubmed: 9865596
Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168
pubmed: 27764560
PLoS One. 2016 Jun 03;11(6):e0156674
pubmed: 27258124
Lancet Infect Dis. 2017 Aug;17(8):854-866
pubmed: 28606591
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Semin Immunopathol. 2019 Mar;41(2):239-249
pubmed: 30547182
CMAJ. 2017 Jun 19;189(24):E819-E827
pubmed: 28630358
Int Health. 2021 Apr 27;13(3):211-214
pubmed: 33709112
Trends Immunol. 2020 Jun;41(6):457-465
pubmed: 32340868
Lancet Infect Dis. 2015 Oct;15(10):1156-1166
pubmed: 26248510
PLoS Pathog. 2008 Nov;4(11):e1000225
pubmed: 19043556
Lancet Infect Dis. 2015 Mar;15(3):356-9
pubmed: 25595637